# Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

> **NCT00367471** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib
- **DRUG:** carboplatin
- **DRUG:** trastuzumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00367471
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-07
- **Primary completion:** 2010-12-22
- **Final completion:** 2019-09-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367471, "Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00367471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*